收费全文 | 7857篇 |
免费 | 768篇 |
国内免费 | 18篇 |
耳鼻咽喉 | 73篇 |
儿科学 | 306篇 |
妇产科学 | 166篇 |
基础医学 | 857篇 |
口腔科学 | 115篇 |
临床医学 | 840篇 |
内科学 | 1225篇 |
皮肤病学 | 102篇 |
神经病学 | 501篇 |
特种医学 | 354篇 |
外科学 | 777篇 |
综合类 | 78篇 |
一般理论 | 3篇 |
预防医学 | 2311篇 |
眼科学 | 137篇 |
药学 | 356篇 |
中国医学 | 4篇 |
肿瘤学 | 438篇 |
2023年 | 51篇 |
2022年 | 77篇 |
2021年 | 104篇 |
2020年 | 137篇 |
2019年 | 112篇 |
2018年 | 173篇 |
2017年 | 165篇 |
2016年 | 165篇 |
2015年 | 191篇 |
2014年 | 185篇 |
2013年 | 334篇 |
2012年 | 253篇 |
2011年 | 265篇 |
2010年 | 247篇 |
2009年 | 252篇 |
2008年 | 254篇 |
2007年 | 269篇 |
2006年 | 294篇 |
2005年 | 250篇 |
2004年 | 273篇 |
2003年 | 219篇 |
2002年 | 274篇 |
2001年 | 251篇 |
2000年 | 211篇 |
1999年 | 313篇 |
1998年 | 219篇 |
1997年 | 241篇 |
1996年 | 257篇 |
1995年 | 177篇 |
1994年 | 98篇 |
1993年 | 155篇 |
1992年 | 128篇 |
1991年 | 110篇 |
1990年 | 130篇 |
1989年 | 131篇 |
1988年 | 121篇 |
1987年 | 109篇 |
1986年 | 129篇 |
1985年 | 106篇 |
1984年 | 75篇 |
1983年 | 65篇 |
1982年 | 55篇 |
1981年 | 56篇 |
1979年 | 92篇 |
1978年 | 66篇 |
1977年 | 63篇 |
1976年 | 66篇 |
1974年 | 52篇 |
1973年 | 56篇 |
1972年 | 51篇 |
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献Main outcome measures In all subjects expiratory volumes were determined and urinary analysis was conducted for hydroxyproline, calcium, phosphorus, and cortisol levels. Osteocalcin, calcium, phosphorus, cortisol, alkaline phosphatase, and γ-glutamyltransferase levels were measured in blood samples. Bone density of the lumbar spine was determined by means of dual-energy x-ray absorptiometry. Nutrition evaluation was based on a 3-day food diary analyzed using progiciel Nutri 91. The nutritional parameters examined were calcium; phosphorus; magnesium; zinc; vitamins A, C, and D; protein; total fiber; oxalates; energy; caffeine; and alcohol in relation to bone density.
Subjects Thirty-one patients with moderate to severe asthma who had been taking more than 1,000 μg beclomethasone per day or the equivalent for more than 2 years and 27 patients with mild asthma who were taking less than 500 μg beclomethasone per day or the equivalent.
Statistical analyses performed Four factor analysis of variance with hierarchized interactions of four levels, Duncan's test, Pearson correlation coefficients.
Results Blood levels of osteocalcin and protein intake were lower in patients with moderate to severe asthma than in those with mild asthma (P<.05). Significant correlations (P<.02) were observed between bone density and calcium intake (r=.40), phosphorus intake (r=.35), protein intake (r=.30), and serum alkaline phosphatase level (r=−.30). Bone density was not significantly different between the two groups of patients with asthma.
Applications A follow-up of patients with asthma who are taking inhaled corticosteroids is needed to assess bone density, osteocalcin levels, and dietary intakes of calcium. Verify if osteocalcin level decreases over time in patients with moderate to severe asthma, monitor possible modifications in bone density, and verify if the correlation between dietary calcium and bone density is maintained. J Am Diet Assoc. 1997;97:1401–1406. 相似文献